AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Alliance to advance development of botulinum toxin vaccines.
2004 JUL 14 - (NewsRx.com & NewsRx.net) -- DOR BioPharma, Inc., (DOR) announced that they, and their academic development partner, Thomas Jefferson University (Jefferson), Philadelphia, Pennsylvania, have entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army's Medical Research Institute of Infectious Diseases (USAMRIID), to advance the development of DOR's mucosally delivered vaccine for botulinum toxin.
The major goal of this CRADA is to develop a safe and effective botulinum toxin vaccine for mucosal (oral or nasal) delivery. Under this agreement, USAMRIID will supply antigens and critical testing reagents and methodologies, while DOR, along with Jefferson, will be responsible for developing and testing formulations suitable for mucosal delivery.
Oral or nasal delivery of the vaccine offers a potential advantage over injectable delivery due to convenience, particularly when mass immunizations are required. There is also scientific evidence to suggest that mucosal delivery of vaccines may confer an added level of protection through mucosal immunity.
The House Select Committee on Homeland Security met on June 3 of this year, and underscored the need to protect America in the wake of the 9/11 attacks, specifically the need to develop countermeasures such as vaccines and treatments against bioterror agents such as botulinum toxin.
"This is an important relationship for DOR," said Ralph Ellison MD, DOR's president and CEO. "The CRADA should allow us to utilize the experience and expertise of USAMRIID to accelerate the development of our mucosally delivered vaccine, which has previously demonstrated 100% protection against botulinum toxin in animal models.
"Since exposure to botulinum toxin is likely to be through ingestion or inhalation, a mucosally delivered vaccine against botulism makes scientific and practical sense. By joining forces we combine our experience and capabilities, and believe this will be the quickest and most efficient route to commercialization of a safe, efficacious and convenient botulinum vaccine," ...
- DOR BioPharma Initiates New Botulinum Toxin Therapeutic Program; Complements...
- Press release article from: Business Wire February 16, 2005 700+ words
...Philadelphia, the inventor of DOR's oral Botulinum toxin vaccine, BT-VACC...world recognized leader in Botulinum toxin research, DOR has entered into an agreement...forward to working with DOR on the Botulinum toxin project," said John...
- DOR BioPharma Executes License Agreement to Recombinant Botulinum Toxin Vaccine...
- Press release article from: Business Wire May 7, 2003 700+ words
...detoxified version of botulinum toxin. DOR's President &...lethal dose of native botulinum toxin. About DOR BioPharma, Inc. DOR...addition to this new oral botulinum toxin vaccine program, DOR has already announced...
- DOR BioPharma Initiates Development of Oral Botulinum Toxin Vaccine.
- Press release article from: Business Wire February 14, 2003 700+ words
...administrable vaccine against botulinum toxin. DOR has executed a letter of...oral vaccination against botulinum toxin." DOR BioPharma, Inc. DOR BioPharma...addition to this new oral botulinum toxin vaccine program, DOR has already announced development...
- DOR BioPharma Announces Publication of Intranasal Version of DOR's Oral Vaccine...
- Press release article from: Business Wire March 11, 2003 700+ words
...Lethal Dose of Inhaled Botulinum Toxin DOR BioPharma Inc. (AMEX...intranasal version of DOR's vaccine against botulinum toxin in the journal Infection...oral and intranasal botulinum toxin vaccine program, DOR is also developing synthetic...
- DOR BioPharma Announces Advances in Mucosal Vaccines for Botulinum Toxin;...
- Press release article from: Business Wire April 7, 2006 700+ words
...serotypes of botulinum toxin, types A and B. DOR is designing...President and CEO of DOR BioPharma, Inc...the addition of botulinum toxin type E serotype...administered botulinum toxin vaccines that...related work, DOR also reports...
- DOR BioPharma Awarded Two Grants Totaling $5.3 Million to Advance Ricin Toxin...
- Press release article from: Business Wire September 29, 2006 700+ words
...corrected release reads: DOR BIOPHARMA AWARDED...ADVANCE RICIN TOXIN AND BOTULINUM TOXIN VACCINE PROGRAMS DOR BioPharma, Inc...BT-VACC[TM] DOR was also awarded a...different serotypes of botulinum toxin for a prototype multivalent...
- DOR BioPharma and Thomas Jefferson University Collaborate With U.S. Army to...
- Press release article from: Business Wire June 16, 2004 700+ words
...the development of DOR's mucosally delivered vaccine for botulinum toxin. The major goal...safe and effective botulinum toxin vaccine for mucosal...methodologies, while DOR, along with Jefferson...bioterror agents such as botulinum toxin. "This is an ...
- DOR BioPharma and Dowpharma enter into a joint development agreement for oral...
- Newspaper article from: BIOTECH Patent News August 1, 2005 700+ words
...the development of DOR's proprietary...against exposure to botulinum toxin, which is one of...civilian population. DOR believes that it...orally delivered botulinum toxin vaccine. Recent...honored to work with DOR to expedite the...important vaccine." Botulinum ...
